{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T20:54:28Z","timestamp":1792011268815,"version":"4.4.0"},"reference-count":89,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,7,7]],"date-time":"2021-07-07T00:00:00Z","timestamp":1625616000000},"content-version":"am","delay-in-days":340,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["UO1 CA185148"],"award-info":[{"award-number":["UO1 CA185148"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["DK120866"],"award-info":[{"award-number":["DK120866"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["RO1 CA221813"],"award-info":[{"award-number":["RO1 CA221813"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["HL118808"],"award-info":[{"award-number":["HL118808"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["RO1 HL134366"],"award-info":[{"award-number":["RO1 HL134366"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["PC170891"],"award-info":[{"award-number":["PC170891"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["W81XWH-18-1-0308"],"award-info":[{"award-number":["W81XWH-18-1-0308"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochimica et Biophysica Acta (BBA) - Reviews on Cancer"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1016\/j.bbcan.2020.188383","type":"journal-article","created":{"date-parts":[[2020,6,11]],"date-time":"2020-06-11T12:33:01Z","timestamp":1591878781000},"page":"188383","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":36,"title":["Cardiovascular risks and toxicity - The Achilles heel of androgen deprivation therapy in prostate cancer patients"],"prefix":"10.1016","volume":"1874","author":[{"given":"Sakthivel","family":"Muniyan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Xi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaustubh","family":"Datta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anindita","family":"Das","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin A.","family":"Teply","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Surinder K.","family":"Batra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rakesh C.","family":"Kukreja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.bbcan.2020.188383_bb0005","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1001\/jamaoncol.2018.2706","article-title":"A Systematic Analysis for the Global Burden of Disease Study","volume":"4","author":"Fitzmaurice","year":"2018","journal-title":"JAMA Oncol"},{"issue":"4","key":"10.1016\/j.bbcan.2020.188383_bb0010","first-page":"271","article-title":"Cancer treatment and survivorship statistics, 2016","volume":"66","author":"Miller","year":"2016","journal-title":"CA Cancer J. Clin."},{"issue":"5","key":"10.1016\/j.bbcan.2020.188383_bb0015","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/j.eururo.2014.07.010","article-title":"Adverse effects of androgen deprivation therapy and strategies to mitigate them","volume":"67","author":"Nguyen","year":"2015","journal-title":"Eur. Urol."},{"issue":"10","key":"10.1016\/j.bbcan.2020.188383_bb0020","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1200\/JOP.18.00178","article-title":"Cardiovascular and metabolic effects of androgen-deprivation therapy for prostate Cancer","volume":"14","author":"Gupta","year":"2018","journal-title":"J Oncol Pract"},{"issue":"19","key":"10.1016\/j.bbcan.2020.188383_bb0025","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1056\/NEJMsa0910784","article-title":"Reimbursement policy and androgen-deprivation therapy for prostate cancer","volume":"363","author":"Shahinian","year":"2010","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.bbcan.2020.188383_bb0030","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1093\/jnci\/djp404","article-title":"Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer","volume":"102","author":"Keating","year":"2010","journal-title":"J. Natl. Cancer Inst."},{"issue":"27","key":"10.1016\/j.bbcan.2020.188383_bb0035","doi-asserted-by":"crossref","first-page":"4448","DOI":"10.1200\/JCO.2006.06.2497","article-title":"Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer","volume":"24","author":"Keating","year":"2006","journal-title":"J. Clin. Oncol."},{"issue":"7","key":"10.1016\/j.bbcan.2020.188383_bb0040","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1002\/cncr.22933","article-title":"Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer","volume":"110","author":"Saigal","year":"2007","journal-title":"Cancer"},{"issue":"17","key":"10.1016\/j.bbcan.2020.188383_bb0045","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1093\/jnci\/djs299","article-title":"Temporal trends in cause of death among Swedish and US men with prostate cancer","volume":"104","author":"Epstein","year":"2012","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.bbcan.2020.188383_bb0050","first-page":"293","article-title":"Studies on prostatic Cancer: I. the effect of castration, of Estrogen and of androgen on serum phosphatases in metastatic carcinoma of the","volume":"1","author":"Huggins","year":"1941","journal-title":"Prostate Cancer Research"},{"issue":"1","key":"10.1016\/j.bbcan.2020.188383_bb0055","doi-asserted-by":"crossref","first-page":"38 e17","DOI":"10.1016\/j.urolonc.2013.03.007","article-title":"Serum testosterone levels after medical or surgical androgen deprivation: a comprehensive review of the literature","volume":"32","author":"Nishiyama","year":"2014","journal-title":"Urol. Oncol."},{"key":"10.1016\/j.bbcan.2020.188383_bb0060","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1146\/annurev.med.45.1.391","article-title":"Gonadotropin-releasing hormone and its analogs","volume":"45","author":"Conn","year":"1994","journal-title":"Annu. Rev. Med."},{"issue":"5","key":"10.1016\/j.bbcan.2020.188383_bb0065","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1073\/pnas.79.5.1658","article-title":"Tumor growth inhibition in patients with prostatic carcinoma treated with luteinizing hormone-releasing hormone agonists","volume":"79","author":"Tolis","year":"1982","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"1","key":"10.1016\/j.bbcan.2020.188383_bb0070","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1177\/1756287212461048","article-title":"Experience with degarelix in the treatment of prostate cancer","volume":"5","author":"Shore","year":"2013","journal-title":"Ther. Adv. Urol."},{"issue":"6","key":"10.1016\/j.bbcan.2020.188383_bb0075","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1016\/j.eururo.2013.12.063","article-title":"Disease control outcomes from analysis of pooled individual patient data from five comparative randomised clinical trials of degarelix versus luteinising hormone-releasing hormone agonists","volume":"66","author":"Klotz","year":"2014","journal-title":"Eur. Urol."},{"issue":"4","key":"10.1016\/j.bbcan.2020.188383_bb0080","doi-asserted-by":"crossref","first-page":"173","DOI":"10.5301\/uro.5000194","article-title":"GNRH-agonist or antagonist in the treatment of prostate cancer: a comparision based on oncological results","volume":"83","author":"Salciccia","year":"2016","journal-title":"Urologia"},{"issue":"11","key":"10.1016\/j.bbcan.2020.188383_bb0085","doi-asserted-by":"crossref","first-page":"H1485","DOI":"10.1152\/ajpheart.00809.2013","article-title":"Testosterone induces apoptosis in vascular smooth muscle cells via extrinsic apoptotic pathway with mitochondria-generated reactive oxygen species involvement","volume":"306","author":"Lopes","year":"2014","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"issue":"7","key":"10.1016\/j.bbcan.2020.188383_bb0090","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1177\/39.7.1865110","article-title":"Androgen receptor expression in human tissues: an immunohistochemical study","volume":"39","author":"Ruizeveld de Winter","year":"1991","journal-title":"J. Histochem. Cytochem."},{"issue":"1","key":"10.1016\/j.bbcan.2020.188383_bb0095","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1530\/JOE-12-0126","article-title":"Effects of androgens on cardiovascular remodeling","volume":"214","author":"Ikeda","year":"2012","journal-title":"J. Endocrinol."},{"issue":"2","key":"10.1016\/j.bbcan.2020.188383_bb0100","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/BF03345150","article-title":"Testosterone and coronary vascular tone: implications in coronary artery disease","volume":"26","author":"Wynne","year":"2003","journal-title":"J. Endocrinol. Investig."},{"issue":"2","key":"10.1016\/j.bbcan.2020.188383_bb0105","doi-asserted-by":"crossref","first-page":"68","DOI":"10.14797\/mdcj-13-2-68","article-title":"Testosterone and the heart","volume":"13","author":"Goodale","year":"2017","journal-title":"Methodist Debakey Cardiovasc J"},{"issue":"3","key":"10.1016\/j.bbcan.2020.188383_bb0110","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1038\/aja.2012.21","article-title":"Testosterone and cardiovascular disease in men","volume":"14","author":"Morris","year":"2012","journal-title":"Asian J Androl"},{"issue":"6b","key":"10.1016\/j.bbcan.2020.188383_bb0115","doi-asserted-by":"crossref","first-page":"E82","DOI":"10.1111\/bju.12732","article-title":"The impact of androgen-deprivation therapy (ADT) on the risk of cardiovascular (CV) events in patients with non-metastatic prostate cancer: a population-based study","volume":"114","author":"Gandaglia","year":"2014","journal-title":"BJU Int."},{"issue":"21","key":"10.1016\/j.bbcan.2020.188383_bb0120","doi-asserted-by":"crossref","first-page":"3448","DOI":"10.1200\/JCO.2010.29.1567","article-title":"Absolute and relative risk of cardiovascular disease in men with prostate cancer: results from the population-based PCBaSe Sweden","volume":"28","author":"Van Hemelrijck","year":"2010","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.bbcan.2020.188383_bb0125","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1016\/j.eururo.2011.08.041","article-title":"Androgen-deprivation therapy and the risk of stroke in patients with prostate cancer","volume":"60","author":"Azoulay","year":"2011","journal-title":"Eur. Urol."},{"issue":"6","key":"10.1016\/j.bbcan.2020.188383_bb0130","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/j.eururo.2012.01.045","article-title":"Androgen-deprivation therapy for nonmetastatic prostate cancer is associated with an increased risk of peripheral arterial disease and venous thromboembolism","volume":"61","author":"Hu","year":"2012","journal-title":"Eur. Urol."},{"issue":"20","key":"10.1016\/j.bbcan.2020.188383_bb0135","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1093\/jnci\/djm168","article-title":"Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality","volume":"99","author":"Tsai","year":"2007","journal-title":"J. Natl. Cancer Inst."},{"issue":"1","key":"10.1016\/j.bbcan.2020.188383_bb0140","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1002\/ejhf.654","article-title":"The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC)","volume":"19","author":"Zamorano","year":"2017","journal-title":"Eur. J. Heart Fail."},{"issue":"4","key":"10.1016\/j.bbcan.2020.188383_bb0145","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/j.eururo.2013.02.002","article-title":"Androgen-deprivation therapy in treatment of prostate cancer and risk of myocardial infarction and stroke: a nationwide Danish population-based cohort study","volume":"65","author":"Jespersen","year":"2014","journal-title":"Eur. Urol."},{"issue":"11","key":"10.1016\/j.bbcan.2020.188383_bb0150","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1200\/JCO.2014.59.1792","article-title":"Risk and timing of cardiovascular disease after androgen-deprivation therapy in men with prostate cancer","volume":"33","author":"O'Farrell","year":"2015","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.bbcan.2020.188383_bb0155","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1111\/bju.13360","article-title":"Risk of thromboembolic disease in men with prostate cancer undergoing androgen deprivation therapy","volume":"118","author":"O'Farrell","year":"2016","journal-title":"BJU Int."},{"issue":"6","key":"10.1016\/j.bbcan.2020.188383_bb0160","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1016\/j.eururo.2017.06.036","article-title":"Gonadotropin-releasing hormone agonists, orchiectomy, and risk of cardiovascular disease: semi-ecologic, Nationwide, population-based study","volume":"72","author":"Thomsen","year":"2017","journal-title":"Eur. Urol."},{"issue":"4","key":"10.1016\/j.bbcan.2020.188383_bb0165","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1001\/jamaoncol.2015.4917","article-title":"Comparison of gonadotropin-releasing hormone agonists and orchiectomy: effects of androgen-deprivation therapy","volume":"2","author":"Sun","year":"2016","journal-title":"JAMA Oncol"},{"issue":"1","key":"10.1016\/j.bbcan.2020.188383_bb0170","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.eururo.2012.08.070","article-title":"Neoadjuvant hormonal therapy use and the risk of death in men with prostate cancer treated with brachytherapy who have no or at least a single risk factor for coronary artery disease","volume":"65","author":"Nanda","year":"2014","journal-title":"Eur. Urol."},{"issue":"8","key":"10.1016\/j.bbcan.2020.188383_bb0175","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1001\/jama.2009.1137","article-title":"Hormonal therapy use for prostate cancer and mortality in men with coronary artery disease-induced congestive heart failure or myocardial infarction","volume":"302","author":"Nanda","year":"2009","journal-title":"JAMA"},{"issue":"21","key":"10.1016\/j.bbcan.2020.188383_bb0180","doi-asserted-by":"crossref","first-page":"3452","DOI":"10.1200\/JCO.2008.20.0923","article-title":"Impact of androgen deprivation therapy on cardiovascular disease and diabetes","volume":"27","author":"Alibhai","year":"2009","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.bbcan.2020.188383_bb0185","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.eururo.2014.11.039","article-title":"Quantifying observational evidence for risk of fatal and nonfatal cardiovascular disease following androgen deprivation therapy for prostate cancer: a meta-analysis","volume":"68","author":"Bosco","year":"2015","journal-title":"Eur. Urol."},{"issue":"4","key":"10.1016\/j.bbcan.2020.188383_bb0190","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1038\/s41391-018-0059-4","article-title":"Association of androgen deprivation therapy with thromboembolic events in patients with prostate cancer: a systematic review and meta-analysis","volume":"21","author":"Guo","year":"2018","journal-title":"Prostate Cancer Prostatic Dis."},{"issue":"21","key":"10.1016\/j.bbcan.2020.188383_bb0195","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1001\/jama.2011.1745","article-title":"Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer: a meta-analysis of randomized trials","volume":"306","author":"Nguyen","year":"2011","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.bbcan.2020.188383_bb0200","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1159\/000334999","article-title":"Androgen deprivation therapy for prostate cancer does not increase cardiovascular mortality in the long term","volume":"82","author":"Wilcox","year":"2012","journal-title":"Oncology"},{"issue":"3","key":"10.1016\/j.bbcan.2020.188383_bb0205","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.eururo.2013.10.032","article-title":"Cardiovascular morbidity associated with gonadotropin releasing hormone agonists and an antagonist","volume":"65","author":"Albertsen","year":"2014","journal-title":"Eur. Urol."},{"issue":"12","key":"10.1016\/j.bbcan.2020.188383_bb0210","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1200\/JCO.2005.04.7423","article-title":"Immediate or deferred androgen deprivation for patients with prostate cancer not suitable for local treatment with curative intent: European Organisation for Research and Treatment of Cancer (EORTC) Trial 30891","volume":"24","author":"Studer","year":"2006","journal-title":"J. Clin. Oncol."},{"issue":"23","key":"10.1016\/j.bbcan.2020.188383_bb0215","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1056\/NEJMoa2004325","article-title":"Oral Relugolix for androgen-deprivation therapy in advanced prostate cancer","volume":"382","author":"Shore","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.bbcan.2020.188383_bb0220","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1097\/01.ju.0000169490.78443.59","article-title":"Hypogonadism and metabolic syndrome: implications for testosterone therapy","volume":"174","author":"Makhsida","year":"2005","journal-title":"J. Urol."},{"issue":"1","key":"10.1016\/j.bbcan.2020.188383_bb0225","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.mayocp.2017.11.006","article-title":"Testosterone and cardiovascular health","volume":"93","author":"Elagizi","year":"2018","journal-title":"Mayo Clin. Proc."},{"issue":"6","key":"10.1016\/j.bbcan.2020.188383_bb0230","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1046\/j.1365-2265.2002.01551.x","article-title":"Long-term effects of androgen deprivation therapy in prostate cancer patients","volume":"56","author":"Basaria","year":"2002","journal-title":"Clin. Endocrinol."},{"issue":"4","key":"10.1016\/j.bbcan.2020.188383_bb0235","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/S1470-2045(13)70025-1","article-title":"Cardiovascular outcomes in patients with locally advanced and metastatic prostate cancer treated with luteinising-hormone-releasing-hormone agonists or transdermal oestrogen: the randomised, phase 2 MRC PATCH trial (PR09)","volume":"14","author":"Langley","year":"2013","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.bbcan.2020.188383_bb0240","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1210\/jcem.87.2.8299","article-title":"Changes in body composition during androgen deprivation therapy for prostate cancer","volume":"87","author":"Smith","year":"2002","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"12","key":"10.1016\/j.bbcan.2020.188383_bb0245","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1016\/0026-0495(90)90190-N","article-title":"Nutritional and metabolic effects of gonadotropin-releasing hormone agonist treatment for prostate cancer","volume":"39","author":"Tayek","year":"1990","journal-title":"Metabolism"},{"issue":"3\u20134","key":"10.1016\/j.bbcan.2020.188383_bb0250","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1080\/13685530500361226","article-title":"The effect of 6 months of androgen deprivation therapy on muscle and fat mass in older men with localized prostate cancer","volume":"8","author":"Boxer","year":"2005","journal-title":"Aging Male"},{"issue":"2","key":"10.1016\/j.bbcan.2020.188383_bb0255","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1007\/s11764-009-0114-1","article-title":"The effect of androgen deprivation therapy on body composition in men with prostate cancer: systematic review and meta-analysis","volume":"4","author":"Haseen","year":"2010","journal-title":"J. Cancer Surviv."},{"issue":"7","key":"10.1016\/j.bbcan.2020.188383_bb0260","doi-asserted-by":"crossref","DOI":"10.1007\/s11883-014-0419-z","article-title":"Insulin resistance, diabetes, and cardiovascular risk","volume":"16","author":"Paneni","year":"2014","journal-title":"Curr. Atheroscler. Rep."},{"issue":"7","key":"10.1016\/j.bbcan.2020.188383_bb0265","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1016\/0026-0495(95)90251-1","article-title":"Contribution of visceral fat mass to the insulin resistance of aging","volume":"44","author":"Cefalu","year":"1995","journal-title":"Metabolism"},{"issue":"5","key":"10.1016\/j.bbcan.2020.188383_bb0270","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1161\/CIRCULATIONAHA.115.012519","article-title":"Cardiovascular effects of androgen deprivation therapy for the treatment of prostate Cancer: ABCDE steps to reduce cardiovascular disease in patients with prostate Cancer","volume":"133","author":"Bhatia","year":"2016","journal-title":"Circulation"},{"issue":"10","key":"10.1016\/j.bbcan.2020.188383_bb0275","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1002\/cncr.23440","article-title":"Metabolic changes during gonadotropin-releasing hormone agonist therapy for prostate cancer: differences from the classic metabolic syndrome","volume":"112","author":"Smith","year":"2008","journal-title":"Cancer"},{"issue":"11","key":"10.1016\/j.bbcan.2020.188383_bb0280","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.urolonc.2015.05.030","article-title":"Cardiovascular risk with androgen deprivation therapy for prostate cancer: potential mechanisms","volume":"33","author":"Tivesten","year":"2015","journal-title":"Urol. Oncol."},{"issue":"3","key":"10.1016\/j.bbcan.2020.188383_bb0285","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1161\/01.CIR.92.3.657","article-title":"Coronary plaque disruption","volume":"92","author":"Falk","year":"1995","journal-title":"Circulation"},{"issue":"16","key":"10.1016\/j.bbcan.2020.188383_bb0290","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1056\/NEJMra043430","article-title":"Inflammation, atherosclerosis, and coronary artery disease","volume":"352","author":"Hansson","year":"2005","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.bbcan.2020.188383_bb0295","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1016\/j.urolonc.2014.06.018","article-title":"GnRH antagonist associates with less adiposity and reduced characteristics of metabolic syndrome and atherosclerosis compared with orchiectomy and GnRH agonist in a preclinical mouse model","volume":"32","author":"Hopmans","year":"2014","journal-title":"Urol. Oncol."},{"key":"10.1016\/j.bbcan.2020.188383_bb0300","doi-asserted-by":"crossref","DOI":"10.1038\/srep26220","article-title":"Treatment with a GnRH receptor agonist, but not the GnRH receptor antagonist degarelix, induces atherosclerotic plaque instability in ApoE(\u2212\/\u2212) mice","volume":"6","author":"Knutsson","year":"2016","journal-title":"Sci. Rep."},{"issue":"2","key":"10.1016\/j.bbcan.2020.188383_bb0305","first-page":"743","article-title":"Human peripheral blood mononuclear cells express gonadotropin-releasing hormone (GnRH), GnRH receptor, and interleukin-2 receptor gamma-chain messenger ribonucleic acids that are regulated by GnRH in vitro","volume":"84","author":"Chen","year":"1999","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"1","key":"10.1016\/j.bbcan.2020.188383_bb0310","doi-asserted-by":"crossref","first-page":"C17","DOI":"10.1152\/ajpcell.00013.2009","article-title":"Gonadotropin-releasing hormone-regulated chemokine expression in human placentation","volume":"297","author":"Cavanagh","year":"2009","journal-title":"Am J Physiol Cell Physiol"},{"issue":"11","key":"10.1016\/j.bbcan.2020.188383_bb0315","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1111\/j.1464-410X.2008.08183.x","article-title":"The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer","volume":"102","author":"Klotz","year":"2008","journal-title":"BJU Int."},{"issue":"3","key":"10.1016\/j.bbcan.2020.188383_bb0320","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1095\/biolreprod.114.118562","article-title":"FSH receptor (FSHR) expression in human extragonadal reproductive tissues and the developing placenta, and the impact of its deletion on pregnancy in mice","volume":"91","author":"Stilley","year":"2014","journal-title":"Biol. Reprod."},{"issue":"3","key":"10.1016\/j.bbcan.2020.188383_bb0325","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1111\/acel.12331","article-title":"FSH regulates fat accumulation and redistribution in aging through the Galphai\/Ca2+\/CREB pathway","volume":"14","author":"Liu","year":"2015","journal-title":"Aging Cell"},{"issue":"2","key":"10.1016\/j.bbcan.2020.188383_bb0330","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1210\/jcem-66-2-308","article-title":"Serum bioactive and immunoreactive follicle-stimulating hormone in prostatic cancer patients during gonadotropin-releasing hormone agonist treatment and after orchidectomy","volume":"66","author":"Huhtaniemi","year":"1988","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"1","key":"10.1016\/j.bbcan.2020.188383_bb0335","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1530\/EJE-09-0366","article-title":"Relationships between FSH, inhibin B, anti-Mullerian hormone, and testosterone during long-term treatment with the GnRH-agonist histrelin in patients with prostate cancer","volume":"162","author":"Eldar-Geva","year":"2010","journal-title":"Eur. J. Endocrinol."},{"issue":"5","key":"10.1016\/j.bbcan.2020.188383_bb0340","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.urolonc.2017.01.025","article-title":"The potential role of follicle-stimulating hormone in the cardiovascular, metabolic, skeletal, and cognitive effects associated with androgen deprivation therapy","volume":"35","author":"Crawford","year":"2017","journal-title":"Urol. Oncol."},{"issue":"4","key":"10.1016\/j.bbcan.2020.188383_bb0345","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1111\/j.1365-2826.2009.01842.x","article-title":"Effects of gonadotrophin-releasing hormone outside the hypothalamic-pituitary-reproductive axis","volume":"21","author":"Skinner","year":"2009","journal-title":"J. Neuroendocrinol."},{"issue":"1","key":"10.1016\/j.bbcan.2020.188383_bb0350","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0304-3835(06)80010-8","article-title":"Expression of gonadotropin-releasing hormone and gonadotropin-releasing hormone receptor mRNAs in various non-reproductive human tissues","volume":"98","author":"Kakar","year":"1995","journal-title":"Cancer Lett."},{"issue":"1","key":"10.1016\/j.bbcan.2020.188383_bb0355","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1006\/frne.1997.0162","article-title":"Mechanism of GnRH receptor signaling: combinatorial cross-talk of Ca2+ and protein kinase C","volume":"19","author":"Naor","year":"1998","journal-title":"Front. Neuroendocrinol."},{"issue":"5","key":"10.1016\/j.bbcan.2020.188383_bb0360","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1111\/j.1365-2826.2011.02119.x","article-title":"The heart: a novel gonadotrophin-releasing hormone target","volume":"23","author":"Dong","year":"2011","journal-title":"J. Neuroendocrinol."},{"issue":"2","key":"10.1016\/j.bbcan.2020.188383_bb0365","doi-asserted-by":"crossref","first-page":"a006023","DOI":"10.1101\/cshperspect.a006023","article-title":"Signaling in muscle contraction","volume":"7","author":"Kuo","year":"2015","journal-title":"Cold Spring Harb. Perspect. Biol."},{"issue":"4","key":"10.1016\/j.bbcan.2020.188383_bb0370","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/S0092-8674(00)80847-8","article-title":"PKA phosphorylation dissociates FKBP12.6 from the calcium release channel (ryanodine receptor): defective regulation in failing hearts","volume":"101","author":"Marx","year":"2000","journal-title":"Cell"},{"issue":"5","key":"10.1016\/j.bbcan.2020.188383_bb0375","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1210\/js.2018-00039","article-title":"Androgen deprivation therapy is associated with prolongation of QTc interval in men with prostate cancer","volume":"2","author":"Gagliano-Juca","year":"2018","journal-title":"J Endocr Soc"},{"issue":"7","key":"10.1016\/j.bbcan.2020.188383_bb0380","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1210\/me.2008-0477","article-title":"GnRH stimulates expression of PACAP in the pituitary gonadotropes via both the PKA and PKC signaling systems","volume":"23","author":"Grafer","year":"2009","journal-title":"Mol. Endocrinol."},{"issue":"2","key":"10.1016\/j.bbcan.2020.188383_bb0385","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1111\/j.1464-410X.1988.tb05062.x","article-title":"Flutamide versus stilboestrol in the management of advanced prostatic cancer. A controlled prospective study","volume":"61","author":"Lund","year":"1988","journal-title":"Br. J. Urol."},{"key":"10.1016\/j.bbcan.2020.188383_bb0390","doi-asserted-by":"crossref","unstructured":"A.B.S. Olga M. Calof, Martin L. Lee, Anne M. Kenny, Randall J. Urban, Joyce L. Tenover, Shalender Bhasin, Adverse events associated with testosterone replacement in middle-aged and older men: a meta-analysis of randomized, placebo-controlled trials, J. Gerontol. 60(11) 1451\u20131457.","DOI":"10.1093\/gerona\/60.11.1451"},{"key":"10.1016\/j.bbcan.2020.188383_bb0395","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.urology.2016.06.024","article-title":"Results from a Multicenter, cross-sectional analysis from the CHOsIng treatment for prostate canCEr (CHOICE) study","volume":"96","author":"Morgia","year":"2016","journal-title":"Urology"},{"issue":"13","key":"10.1016\/j.bbcan.2020.188383_bb0400","doi-asserted-by":"crossref","first-page":"12944","DOI":"10.1074\/jbc.M404706200","article-title":"Phosphodiesterase-5 inhibitor sildenafil preconditions adult cardiac myocytes against necrosis and apoptosis. Essential role of nitric oxide signaling","volume":"280","author":"Das","year":"2005","journal-title":"J. Biol. Chem."},{"issue":"43","key":"10.1016\/j.bbcan.2020.188383_bb0405","doi-asserted-by":"crossref","first-page":"29572","DOI":"10.1074\/jbc.M801547200","article-title":"Protein kinase G-dependent cardioprotective mechanism of phosphodiesterase-5 inhibition involves phosphorylation of ERK and GSK3beta","volume":"283","author":"Das","year":"2008","journal-title":"J. Biol. Chem."},{"issue":"3","key":"10.1016\/j.bbcan.2020.188383_bb0410","doi-asserted-by":"crossref","first-page":"H1398","DOI":"10.1152\/ajpheart.ajpheart.91438.2007","article-title":"Sildenafil (Viagra) attenuates ischemic cardiomyopathy and improves left ventricular function in mice","volume":"294","author":"Salloum","year":"2008","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"issue":"13","key":"10.1016\/j.bbcan.2020.188383_bb0415","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1161\/01.CIR.0000160359.49478.C2","article-title":"Phosphodiesterase-5 inhibition with sildenafil attenuates cardiomyocyte apoptosis and left ventricular dysfunction in a chronic model of doxorubicin cardiotoxicity","volume":"111","author":"Fisher","year":"2005","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.bbcan.2020.188383_bb0420","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1124\/jpet.110.170191","article-title":"Long-acting phosphodiesterase-5 inhibitor tadalafil attenuates doxorubicin-induced cardiomyopathy without interfering with chemotherapeutic effect","volume":"334","author":"Koka","year":"2010","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"42","key":"10.1016\/j.bbcan.2020.188383_bb0425","doi-asserted-by":"crossref","first-page":"18202","DOI":"10.1073\/pnas.1006965107","article-title":"Sildenafil increases chemotherapeutic efficacy of doxorubicin in prostate cancer and ameliorates cardiac dysfunction","volume":"107","author":"Das","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"4","key":"10.1016\/j.bbcan.2020.188383_bb0430","doi-asserted-by":"crossref","first-page":"4399","DOI":"10.18632\/oncotarget.6749","article-title":"Sildenafil (Viagra) sensitizes prostate cancer cells to doxorubicin-mediated apoptosis through CD95","volume":"7","author":"Das","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.bbcan.2020.188383_bb0435","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.pharmthera.2014.10.003","article-title":"PDE5 inhibitors as therapeutics for heart disease, diabetes and cancer","volume":"147","author":"Das","year":"2015","journal-title":"Pharmacol. Ther."},{"issue":"11","key":"10.1016\/j.bbcan.2020.188383_bb0440","doi-asserted-by":"crossref","first-page":"4423","DOI":"10.1182\/blood-2002-10-3210","article-title":"A predominant role for cAMP-dependent protein kinase in the cGMP-induced phosphorylation of vasodilator-stimulated phosphoprotein and platelet inhibition in humans","volume":"101","author":"Li","year":"2003","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.bbcan.2020.188383_bb0445","doi-asserted-by":"crossref","first-page":"e645","DOI":"10.1016\/j.clgc.2017.12.007","article-title":"The cardiovascular toxicity of Abiraterone and Enzalutamide in prostate cancer","volume":"16","author":"Iacovelli","year":"2018","journal-title":"Clin. Genitourin Cancer"}],"container-title":["Biochimica et Biophysica Acta (BBA) - Reviews on Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304419X20301025?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304419X20301025?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T13:00:11Z","timestamp":1777554011000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304419X20301025"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8]]},"references-count":89,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["S0304419X20301025"],"URL":"https:\/\/doi.org\/10.1016\/j.bbcan.2020.188383","relation":{},"ISSN":["0304-419X"],"issn-type":[{"value":"0304-419X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cardiovascular risks and toxicity - The Achilles heel of androgen deprivation therapy in prostate cancer patients","name":"articletitle","label":"Article Title"},{"value":"Biochimica et Biophysica Acta (BBA) - Reviews on Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbcan.2020.188383","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"188383"}}